Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

Rankning i aktier #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Aktiekurs
$6.89
Marknadsvärde
$43.94B
Förändring (1 dag)
-2.91%
Förändring (1 år)
-24.78%
Land
CN
Handel Jiangsu Hengrui Medicine Co., Ltd. (600276)

Kategori

Healthcare
P/S-tal för Jiangsu Hengrui Medicine Co., Ltd. (600276)
P/S-tal per October 2026 TTM: 9.37
Enligt Jiangsu Hengrui Medicine Co., Ltd. senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 9.37. I slutet av 2024 hade företaget ett P/S-tal på 10.39.
Historik för P/S-tal för Jiangsu Hengrui Medicine Co., Ltd. från 2001 till 2026
P/S-tal vid årets slut
År P/S-tal Ändra
2026 (TTM) 9.37 -23.96%
2025 12.32 18.54%
2024 10.39 -17.13%
2023 12.54 8.76%
2022 11.53 -7.68%
2021 12.49 -41.32%
2020 21.29 28.72%
2019 16.54 47.69%
2018 11.20 -3.36%
2017 11.59 44.55%
2016 8.02 -6.62%
2015 8.58 63.97%
2014 5.24 -9.71%
2013 5.80 21.57%
2012 4.77 -5.76%
2011 5.06 -38.70%
2010 8.26 10.18%
2009 7.49 29.72%
2008 5.78 -34.42%
2007 8.81 78.87%
2006 4.92 420.22%
2005 0.95 14.31%
2004 0.83 -8.27%
2003 0.90 -28.02%
2002 1.25 -16.11%
2001 1.50 0.00%
P/S-tal för liknande företag eller konkurrenter